The BAP1 wild-type MPM cell line CRL-2081 was significantly less sensitive to olaparib than to niraparib (Fig. 1d, e), consistent with the benefit niraparib demonstrated in ovarian cancers that were not deficient in BRCA1 or 2 [19]. This evidence concerns the gene BAP1 and ovarian cancer.